微芯生物：西达本胺授权Nizhpharm，首付款达1000万元

Core Viewpoint - Microchip Biotech has signed a licensing and distribution agreement with Nizhny Novgorod Chemical Pharmaceutical Plant (Nizhpharm) for the commercialization of Sidabenamine in multiple authorized regions [1] Group 1: Agreement Details - Nizhpharm will obtain exclusive rights for the research, registration, and commercialization of Sidabenamine in the specified regions [1] - Nizhpharm is responsible for the product's research, market registration, secondary packaging, transportation, and commercial sales in the authorized areas [1] Group 2: Financial Aspects - The company will receive an initial payment of 10 million RMB upon the agreement's effectiveness [1] - Additional milestone payments include 10 million RMB for the transfer of regulatory materials and another 10 million RMB for local registration and market launch [1] Group 3: Company Background - Nizhpharm is one of the leading pharmaceutical companies in the Russian Federation, with over a century of history [1]